Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to ...

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...

Catalent provides contract manufacturing services and performs fill-finish work, which involves the sterile filling and ...

Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey: Ghent, Belgium Tuesday, October 15, 2024, 16:00 Hrs [IST] Ardena, a specialist pha ...

The FDA-approved Somerset facility employs approximately 200 skilled scientists and technicians and is a Center of Excellence for advanced delivery of oral dosage forms, complementing Ardena's ...

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said. ** Private equity ...

Based in Somerset, New Jersey, Catalent, Inc. (CTLT) develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products. Valued at a ...

Kinaxis® , a global leader in end-to-end supply chain orchestration, today announced a co-development deal with ExxonMobil, one of the largest integrated fuels, lubricants and chemical companies in ...

The company was founded in April 2007 and is headquartered in Somerset, NJ. Read More on CTLT: Catalent NewsMORE Related Stocks Indices Commodities Currencies ...